23989093|t|Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials.
23989093|a|BACKGROUND: Use of dexmedetomidine or propofol rather than a benzodiazepine sedation strategy may improve ICU outcomes. We reviewed randomized trials comparing a benzodiazepine and nonbenzodiazepine regimen in mechanically ventilated adult ICU patients to determine if differences exist between these sedation strategies with respect to ICU length of stay, time on the ventilator, delirium prevalence, and short-term mortality. METHODS: We searched CINAHL, MEDLINE, the Cochrane databases, and the American College of Critical Care Medicine's Pain, Agitation, Delirium Management Guidelines' literature database from 1996 to 2013. Citations were screened for randomized trials that enrolled critically ill, mechanically ventilated adults comparing an IV benzodiazepine-based to a nonbenzodiazepine-based sedative regimen and reported duration of ICU length of stay, duration of mechanical ventilation, delirium prevalence, and/or short-term mortality. Trial characteristics and results were abstracted in duplicate and independently, and the Cochrane risk of bias tool was used for quality assessment. We performed random effects model meta-analyses where possible. RESULTS: We included six trials enrolling 1,235 patients: midazolam versus dexmedetomidine (n = 3), lorazepam versus dexmedetomidine (n = 1), midazolam versus propofol (n = 1), and lorazepam versus propofol (n = 1). Compared to a benzodiazepine sedative strategy, a nonbenzodiazepine sedative strategy was associated with a shorter ICU length of stay (n = 6 studies; difference = 1.62 d; 95% CI, 0.68-2.55; I = 0%; p = 0.0007) and duration of mechanical ventilation (n = 4 studies; difference = 1.9 d; 95% CI, 1.70-2.09; I2 = 0%; p < 0.00001) but a similar prevalence of delirium (n = 2; risk ratio = 0.83; 95% CI, 0.61-1.11; I2 = 84%; p = 0.19) and short-term mortality rate (n = 4; risk ratio = 0.98; 95% CI, 0.76-1.27; I2 = 30%; p = 0.88). CONCLUSIONS: Current controlled data suggest that use of a dexmedetomidine- or propofol-based sedation regimen rather than a benzodiazepine-based sedation regimen in critically ill adults may reduce ICU length of stay and duration of mechanical ventilation. Larger controlled studies are needed to further define the impact of nonbenzodiazepine sedative regimens on delirium and short-term mortality.
23989093	0	14	Benzodiazepine	Chemical	MESH:D001569
23989093	22	39	nonbenzodiazepine	Chemical	-
23989093	84	98	critically ill	Disease	MESH:D016638
23989093	186	201	dexmedetomidine	Chemical	MESH:D020927
23989093	205	213	propofol	Chemical	MESH:D015742
23989093	228	242	benzodiazepine	Chemical	MESH:D001569
23989093	329	343	benzodiazepine	Chemical	MESH:D001569
23989093	348	365	nonbenzodiazepine	Chemical	-
23989093	411	419	patients	Species	9606
23989093	548	556	delirium	Disease	MESH:D003693
23989093	584	593	mortality	Disease	MESH:D003643
23989093	710	714	Pain	Disease	MESH:D010146
23989093	716	725	Agitation	Disease	MESH:D011595
23989093	727	735	Delirium	Disease	MESH:D003693
23989093	858	872	critically ill	Disease	MESH:D016638
23989093	921	935	benzodiazepine	Chemical	MESH:D001569
23989093	947	964	nonbenzodiazepine	Chemical	-
23989093	1069	1077	delirium	Disease	MESH:D003693
23989093	1108	1117	mortality	Disease	MESH:D003643
23989093	1381	1389	patients	Species	9606
23989093	1391	1400	midazolam	Chemical	MESH:D008874
23989093	1408	1423	dexmedetomidine	Chemical	MESH:D020927
23989093	1433	1442	lorazepam	Chemical	MESH:D008140
23989093	1450	1465	dexmedetomidine	Chemical	MESH:D020927
23989093	1475	1484	midazolam	Chemical	MESH:D008874
23989093	1492	1500	propofol	Chemical	MESH:D015742
23989093	1514	1523	lorazepam	Chemical	MESH:D008140
23989093	1531	1539	propofol	Chemical	MESH:D015742
23989093	1563	1577	benzodiazepine	Chemical	MESH:D001569
23989093	1599	1616	nonbenzodiazepine	Chemical	-
23989093	1904	1912	delirium	Disease	MESH:D003693
23989093	1994	2003	mortality	Disease	MESH:D003643
23989093	2135	2150	dexmedetomidine	Chemical	MESH:D020927
23989093	2155	2163	propofol	Chemical	MESH:D015742
23989093	2201	2215	benzodiazepine	Chemical	MESH:D001569
23989093	2242	2256	critically ill	Disease	MESH:D016638
23989093	2403	2420	nonbenzodiazepine	Chemical	-
23989093	2442	2450	delirium	Disease	MESH:D003693
23989093	2466	2475	mortality	Disease	MESH:D003643
23989093	Negative_Correlation	MESH:D020927	MESH:D016638
23989093	Cotreatment	MESH:D008874	MESH:D020927
23989093	Negative_Correlation	MESH:D015742	MESH:D016638
23989093	Cotreatment	MESH:D008140	MESH:D020927
23989093	Cotreatment	MESH:D008874	MESH:D015742
23989093	Negative_Correlation	MESH:D001569	MESH:D016638

